Jamie Mark Grooms Sells 84,295 Shares of AxoGen, Inc. (AXGN) Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Jamie Mark Grooms sold 84,295 shares of the firm’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $26.38, for a total value of $2,223,702.10. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Jamie Mark Grooms also recently made the following trade(s):

  • On Wednesday, December 6th, Jamie Mark Grooms sold 21,290 shares of AxoGen stock. The shares were sold at an average price of $26.22, for a total value of $558,223.80.

Shares of AxoGen, Inc. (AXGN) opened at $26.20 on Friday. The company has a debt-to-equity ratio of 1.93, a current ratio of 3.55 and a quick ratio of 2.95. AxoGen, Inc. has a twelve month low of $8.15 and a twelve month high of $27.60.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). AxoGen had a negative return on equity of 91.00% and a negative net margin of 24.74%. The business had revenue of $16.05 million during the quarter, compared to the consensus estimate of $15.55 million. The business’s quarterly revenue was up 43.2% on a year-over-year basis. equities analysts anticipate that AxoGen, Inc. will post -0.31 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its stake in shares of AxoGen by 80.7% in the second quarter. Bank of New York Mellon Corp now owns 160,354 shares of the medical equipment provider’s stock worth $2,685,000 after purchasing an additional 71,609 shares during the last quarter. Bradley Foster & Sargent Inc. CT raised its stake in shares of AxoGen by 536.6% in the second quarter. Bradley Foster & Sargent Inc. CT now owns 78,905 shares of the medical equipment provider’s stock worth $1,322,000 after purchasing an additional 66,510 shares during the last quarter. Menta Capital LLC raised its stake in shares of AxoGen by 7.1% in the second quarter. Menta Capital LLC now owns 116,845 shares of the medical equipment provider’s stock worth $1,957,000 after purchasing an additional 7,777 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of AxoGen in the second quarter worth about $947,000. Finally, New York State Common Retirement Fund raised its stake in shares of AxoGen by 26.6% in the second quarter. New York State Common Retirement Fund now owns 31,400 shares of the medical equipment provider’s stock worth $526,000 after purchasing an additional 6,599 shares during the last quarter. Hedge funds and other institutional investors own 66.00% of the company’s stock.

A number of equities research analysts recently weighed in on the company. Jefferies Group assumed coverage on AxoGen in a research report on Thursday, November 30th. They set a “buy” rating and a $35.00 price objective on the stock. Leerink Swann raised their price target on AxoGen from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, November 21st. Lake Street Capital raised their price target on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 21st. Wedbush reissued a “buy” rating and issued a $27.00 price target (up previously from $22.00) on shares of AxoGen in a report on Tuesday, November 21st. Finally, Roth Capital reissued a “buy” rating and issued a $21.00 price target (up previously from $18.00) on shares of AxoGen in a report on Tuesday, September 12th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $26.17.

COPYRIGHT VIOLATION WARNING: “Jamie Mark Grooms Sells 84,295 Shares of AxoGen, Inc. (AXGN) Stock” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/10/jamie-mark-grooms-sells-84295-shares-of-axogen-inc-axgn-stock.html.

About AxoGen

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply